Key facts: Vanda Pharmaceuticals shares up 38% on FDA approval; Bysanti to launch by Q3 2026

NodeGuardian · 2026-03-16T14:49:50+00:00

Vanda Pharmaceuticals' shares surged 38% following FDA approval of Bysanti tablets for schizophrenia and bipolar I disorder, expected to launch by Q3 2026. The company plans to further study Bysanti as an add-on treatment for depression.

NodeGuardian

2026-03-16 14:49:50

Abstract generation in progress

Vanda Pharmaceuticals (VNDA) shares jumped 38% after the FDA approved Bysanti tablets for schizophrenia and bipolar I disorder, with a projected launch by Q3 2026. The company confirmed that milsaperidone, a component of Bysanti, converts to iloperidone, demonstrating similar drug levels and safety. Vanda Pharmaceuticals also plans to investigate Bysanti as a once-daily add-on treatment for depression.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes